Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control

The current enhanced permeability and retention (EPR)-based approved nanomedicines have had little impact in terms of prolongation of overall survival in patients with cancer. For example, the two Phase III trials comparing Doxil(®), the first nanomedicine approved by the US Food and Drug Administra...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yao An, Shyu, Ing Luen, Lu, Maggie, He, Chun Lin, Hsu, Yen Mei, Liang, Hsiang Fa, Liu, Chih Peng, Liu, Ren Shyan, Shen, Biing Jiun, Wei, Yau Huei, Chuang, Chi Mu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386769/
https://www.ncbi.nlm.nih.gov/pubmed/25848266
http://dx.doi.org/10.2147/IJN.S78321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386769/
https://www.ncbi.nlm.nih.gov/pubmed/25848266
http://dx.doi.org/10.2147/IJN.S78321

Ejemplares similares